![](https://investorshub.advfn.com/uicon/113775.png?cb=1640546002)
Tuesday, July 07, 2020 6:00:44 PM
No trials can be run without drugs manufactured for use in trials. They have a history of manufacturing drugs since they have a history of running trials. It's absolutely true.
The problem they are facing now is that covid came as a surprise to everyone. Prior to covid, the focus was on Brilacidin OM and UC. Manufacturing arrangements were focused on sachets for OM and oral dosing for UC. As can be seen in recent pr's they are in the manufacturing process for Brilacidin dosing via intravenous (IV) for use in a covid trial. Lack of enough IV drug on hand is likely the reason they haven't been in a covid clinical trial yet. And, that isn't surprising since Leo had no way to anticipate a global covid pandemic.
One of the questions in my mind is which trial do we see first? Brilacidin IV for covid or Brilacidin oral for UC?
Good luck to all and stay safe.
Message in reply to: bolded
"It makes perfect sense to have started manufacturing already. What wouldn't make sense is to not start it when they know they'll need it whether they partner up or go it alone with grant funds. No trials without drugs."
Haven't they pre started B for sachets for OM, and one other indication in another form (than sachets) first (sorry, forget which one)?
What makes you think this is true, and shall "pan out"?
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM